Publications by authors named "Sebastian Blaj"
Background: Advanced gastric cancer with synchronous peritoneal metastases (GC-PM) is associated with a poor prognosis. Although cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a promising approach, only a limited number of Western studies exist.
Aim: To investigate the clinicopathological outcomes of patients who underwent CRS-HIPEC for GC-PM.
Introduction: Primary treatment for peritoneal dissemination of appendiceal cancer is the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The endpoints were overall survival and evaluation of prognostic factors.
Methods: Clinicopathological and treatment-related factors were obtained from a prospective database.
Background: Pseudomyxoma peritonei (PMP) is a rare peritoneal condition where mucus-secreting tumorous cells progressively produce a thick, gelatin-like substance. The prognosis of patients with PMP is determined by the degree of cellularity within the mucin (low-grade (LAMN) vs. high-grade (HAMN) histologic features) and by the extent of the disease.
View Article and Find Full Text PDFBackground/aim: The aim of the study was to assess diagnostic tools implemented in selecting candidates for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with special emphasis on diagnostic laparoscopy.
Patients And Methods: A total of 229 patients underwent laparoscopy between January 2011 and December 2015 with peritoneal carcinomatosis and were analyzed retrospectively to study the role of laparoscopy in selecting patients for CRS and HIPEC.
Results: After initial laparoscopy, 101 (44%) of patients underwent CRS and HIPEC with 128 (56%) being aborted.
Background/aim: This study compared the perioperative outcomes after the same combination of hyperthermic intraperitoneal chemotherapy (HIPEC) compounds when administered for 90 min vs. 60 min, while all other therapy variables remained constant.
Patients And Methods: A total of 120 patients were included with peritoneal surface malignancy who underwent cisplatin (75 mg/m) and doxorubicin (15 mg/m) closed HIPEC after cytoreductive surgery.
Article Synopsis
- The study aimed to evaluate how operating room (OR) teams perceive risks and adopt safety measures when conducting hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC).
- Conducted among OR teams from ten high-volume centers across six countries, the survey collected responses from various professionals, revealing that individual protection measure uptake was low at 51.4%.
- While PIPAC had a higher perceived protection level, all groups, particularly cleaning staff and anesthesiologists, showed a desire for more information, highlighting the need for better training on safety protocols in these procedures.
Purpose: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC.
View Article and Find Full Text PDF